Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Scientists Find Gene that Causes Drug Resistance in Cancer

Published: Wednesday, January 16, 2013
Last Updated: Wednesday, January 16, 2013
Bookmark and Share
The discovery is a first step in creating new, effective therapeutic treatments for sufferers of aggressive cancers.

“There are not a lot of options for cancer patients with diseases such as myeloma,” said BYU biology professor David Bearss, a coauthor on the study published Jan. 14 in the journal Cancer Cell. “Myeloma is not only an extremely painful cancer, but it is also a disease that is resistant to treatment.”

Multiple myeloma is a cancer of plasma cells that exists exclusively in the bone. Over time the cancer cells take over bone marrow and destroy its function. This results in major health problems, including failure of the immune system, loss of kidney function, a drop in red blood cell count and large soft spots or holes that form in bones. These holes lead to painful fractures throughout the body, from the skull to hips to the spine.

Compounding that pain for patients is that myeloma cells quickly become resistant to chemotherapy and other drugs, resulting in a short life expectancy for those diagnosed. Over the last few years lead researchers Fenghuang (Frank) Zhan and Guido Tricot, along with Bearss, have been trying to figure out how the disease develops drug resistance.

For the Cancer Cell study, the team carried out a genomic analysis of the biopsied cells of 19 myeloma patients, taken from different stages of their cancer development. They wanted to see what was happening on the genetic level as the disease progressed.

They found that patients with the most aggressive forms of myeloma, and the patients with the poorest drug response, were those who had a high expression of the gene NEK2. That finding led the team to start going after the gene in the lab to see what would happen.

“Silencing NEK2 in cancer cells potently decreased drug resistance, induced cell-cycle arrest, cell death, and inhibition of cancer cell growth in vitro and in vivo," said Zhan, professor of internal medicine at University of Iowa’s Carver College of Medicine.

Added Bearss: “We were able to show that if we inhibit NEK2, then we can actually restore sensitivity to drugs that we use right now.”

The research results also indicate that NEK2 can be used in diagnostic testing.

“We’ve found that this gene is not just a predictor of poor therapy response in myeloma, but is a predictor to poor response in other cancers, such as breast cancer, lung cancer and other major tumor types,” Bearss said. “A big take home from this study is that we could potentially use NEK2 for early screening of patients so we could treat patients with higher levels more aggressively.”

Bearss and his BYU undergraduate student team are now working toward the development of drugs that specifically target NEK2. Their hope is to develop a compound that is minimally toxic to normal cells while having a high selectivity to cancer cells.

The Iowa-BYU research team is currently in the third year of a five-year National Institute of Health grant. The goal is to be ready to take newly formed compounds into human studies by the end of the grant period.

"This study shows convincingly that genomic changes over time are culprit in more aggressive cancer behavior,” said Dr. Rafael Fonseca, Chair of the Department of Medicine at Mayo Clinic in Arizona, who was not involved in the study. “It is likely that for cancers the major risk factors for poor prognosis are not the specific cancer genetic changes, but rather the ability of any given cancer to change, mutate and evolve."

A good portion of Professor Bearss’ contribution to this research study occurred while he was Co-Director of the Center for Investigational Therapeutics and an associate professor of oncology at the University of Utah’s Huntsman Institute of Cancer. Collaborators Zhan and Tricot were also both formerly at the Huntsman Cancer Institute.

Dr. Tricot currently serves as the director of Holden Comprehensive Cancer Center’s Bone Marrow Transplant and Myeloma Program at University of Iowa Hospitals and Clinics.

Bearss joined BYU’s Department of Physiology and Developmental Biology in the fall of 2012, after three years as a professor at the Huntsman Cancer Institute.

Dr. Bearss also served on the faculty of the University of Arizona and has founded and led numerous pharmaceutical startup companies during his career.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
GMO Food Animals Should be Judged by Product, Not Process
In a world with a burgeoning demand for meat, milk and eggs, regulatory policies around the use of biotechnologies in agriculture need to be based on the safety and attributes of those foods rather than on the methods used to produce them, says a UC Davis animal scientist.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
Gene Drive Reversibility Introduces New Layer of Biosafety
Ability to introduce or reverse the spread of genetic traits through populations could one day improve pest management and disease control.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos